Roles
- Professor of Clinical Ophthalmology
-
Biography
Ellen Koo, M.D., is a cornea and cataract specialist who has made significant contributions to the subspecialty field of cornea. She is committed to improving the field of cornea transplantation and eye banking and has pioneered innovations in the surgical techniques of Descemet Membrane Endothelial Keratoplasty (DMEK) and Descemet’s Stripping Endothelial Keratoplasty. Koo teaches the DMEK procedure to other surgeons and serves as a speaker and panelist at national meetings. She is past-president of the Fuchs Symposium committee—a committee made up of experts and thought leaders in Fuchs Endothelial Corneal Dystrophy and serves on the board of directors of KeraLink. She is currently a principal investigator of a research study investigating the presence of the COVID-19 virus and associated clinical effects in patients undergoing anterior segment surgery. -
Education & Training
Education
-
Research Interests
Fuchs Dystrophy
DMEK/DSAEK Surgery
Keratoconus -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 7 clinical trials.
-
This is a standardized, multicenter, observational study (OS) for subjects diagnosed with FECD. This OS will consist of longitudinal data collection on disease status of subjects over a period of approximately 2 years. No investigational product will be administered. To provide additional longitudinal data documenting FECD disease progression, retrospective data (eg, from medical records or archived images) will be collected for the clinical assessments, as available.The study is intended to evaluate subjects representing the entire spectrum of disease severity, from recently diagnosed, asymptomatic individuals to people living with more advanced FECD who are preparing for keratoplasty (eg, Descemet’s membrane endothelial keratoplasty [DMEK] or Descemet’smembrane stripping only [DSO]). Throughout study enrollment, the Sponsor will track severity across the enrolled disease population and may cap enrollment for specific demographics and/or characteristics to ensure a representative distribution across the spectrum of disease severity.
- Principal Investigator: Ellen Koo
- Study Phase: TBD
- Enrollment Status: Open
-
The study will test Ripasudil ophthalmic solution 0.4% (K-321) which has been marketed in Japan since December 2014 as Glanatec. K-321 is a selective inhibitor of a protein called Rho-kinase (ROCK) which has been demonstrated to help wounds heal faster. It has also been shown to improve corneal health and visual outcomes in several studies in FECD subjects undergoing descemetorhexis alone.
- Principal Investigator: Ellen Koo
- Study Phase: TBD
- Enrollment Status: Closed
-
The purpose of this research is to identify the best treatment for patients with diseased or damaged endothelium requiring corneal transplant. Currently, it is not known which type of transplant is the best. In this study we will determine differences in visual outcomes between two types of corneal transplant surgeries, ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK), and to determine the effect of rho-kinase inhibitors on endothelial cell loss.
- Principal Investigator: Ellen Koo
- Study Phase: TBD
- Enrollment Status: Open
-
The purpose of this study is to compare the safety and effectiveness of the study product, CSB-001 ophthalmic solution 0.1% to placebo when treating stage 2 and 3 Neurotrophic Keratitis.
- Principal Investigator: Ellen Koo
- Study Phase: TBD
- Enrollment Status: Closed
-
This is a double-masked, randomized, placebo-controlled, parallel-group, multi-center two-period study in subjects with Fuchs Endothelial Corneal Dystrophy (FECD) after descemetorhexis. The treatment groups consist of K-321 ophthalmic solution 0.4% four times daily (QID) and a placebo group. After the screening period and descemetorhexis procedure of the study eye on Day -1, the first period of the study is the treatment period, consisting of randomization and initiation of treatment visit and a 12-week treatment phase. The second period of the study is a 40-week follow-up period with a 2-week medication taper phase.
- Principal Investigator: Ellen Koo
- Study Phase: TBD
- Enrollment Status: Closed
-
Diabetes Endothelial Keratoplasty Study (DEKS): Impact of Diabetes on Corneal Transplant Success and Endothelial Cell Loss
- Principal Investigator: Ellen Koo
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Phase 1, Prospective, Multi-Center, Open-Label, Dose-Escalation Study to Assess the Safety, and Tolerability of EO2002 With and Without Endothelial Brushing or Descemet Stripping in the Treatment of Corneal Edema (EMME-001)
- Principal Investigator: Ellen Koo
- Study Phase: Phase 1
- Enrollment Status: Closed